18 June, 10:30-11:15

Integrating preventive diagnostics into routine care is vital to improving patient outcomes and system flow, particularly in time-critical pathways such as secondary stroke prevention. Point-of-care testing ensures results are available before discharge, so teams can optimise treatment immediately.

Sponsored by and produced withGenedrive_Logo_RGB

While evidence for improved outcomes is clear, adoption across systems remains variable. Both clinical and non-clinical leaders have a unique opportunity to work together and bridge the gap between evidence and implementation.

This HSJ webinar will demonstrate how rapid point-of-care pharmacogenetic testing can and has already been successfully embedded into routine care in Manchester.

Join Dwaipayan Sen, consultant in stroke medicine at Greater Manchester Comprehensive Stroke Centre, and John McDermott, National Institute for Health and Care Research academic clinical lecturer at Manchester Centre for Genomic Medicine, to hear about the clinical impact of rapid testing and the pathway to local adoption.

This case study-led discussion will:

  • Set out the clinical case for rapid pharmacogenetic testing
  • Demonstrate how NHS organisations have operationalised testing within existing pathways
  • Provide practical guidance on next steps to support adoption

Viewers will also be able to submit their questions during the open Q&A session.

Panellists

Biosmall[1]

John McDermott, NIHR academic clinical lecturer at Manchester Centre for Genomic Medicine

John McDermott is an NIHR academic clinical lecturer at the University of Manchester and a clinical genetics specialty registrar. He was appointed as the UK’s first academic clinical fellow in Genomic Medicine in 2016 under the supervision of William Newman. Working at the Manchester Centre for Genomic Medicine, his research focuses on the application of genetic and genomic technologies in the acute and everyday healthcare settings – specifically focusing on the integration of pharmacogenomics into routine practice.

Portrait of Dr Dwaipayan Sen , Consultant Geriatrician[1]

Dwaipayan Sen, consultant in stroke medicine at Greater Manchester Comprehensive Stroke Centre

Dwaipayan Sen has served as a consultant in stroke medicine at the Greater Manchester Comprehensive Stroke Centre in Salford Royal Hospital since 2014. He has led the service as clinical director between 2022 and 2025, while developing a 24/7 thrombectomy service for Greater Manchester. His international contributions include serving as director of stroke services at the Institute of Neurosciences in Calcutta and developing thrombectomy services in the city. Dr Sen has a keen interest in cerebral small vessel disease and, over the last five years, has developed a regional tertiary small vessel disease service and neurogenetic service in Salford. His other area of interest is the use of pharmacogenomics in secondary prevention of stroke. He has led the national pilot for the use of CYP2C19 in guiding antiplatelet strategy for secondary prevention of stroke.

Claire Read Photo

Claire Read, contributor, HSJ   (webinar chair)

Claire Read is a professional writer and editor who has specialised in healthcare throughout her 20-year career. She has been a regular contributor to HSJ  since 2012 and has a particular interest in healthcare digitisation and technology.

To register for this webinar, please complete the form below.